Lexeo Therapeutics Inc
LXEO7.160USD
+0.270+3.92%
Cierre 02/06, 16:00（ET）Cotizaciones retrasadas 15 min
393.31MCap. mercado
PérdidaP/E TTM
Más Datos de Lexeo Therapeutics Inc Compañía
Lexeo Therapeutics, Inc. is a clinical-stage genetic medicine company dedicated to transforming healthcare by applying pioneering science to fundamentally change how genetically defined cardiovascular diseases and APOE4-associated Alzheimers disease are treated. Using a stepwise development approach, the Company is leveraging early proof-of-concept functional and biomarker data to advance a pipeline of cardiovascular and APOE4-associated Alzheimers disease programs. Its pipeline consists of candidates targeting patient populations. Its most advanced cardiovascular product candidate, LX2006 for the treatment of patients with Friedreichs ataxia (FA), cardiomyopathy, is being evaluated in SUNRISE-FA, an ongoing Phase I/II clinical trial. Its second most advanced cardiovascular product candidate, LX2020 for the treatment of arrhythmogenic cardiomyopathy, caused by mutations in the PKP2 gene (PKP2-ACM), received IND clearance from the United States Food and Drug Administration (FDA).
Información de Lexeo Therapeutics Inc
Símbolo de cotizaciónLXEO
Nombre de la empresaLexeo Therapeutics Inc
Fecha de salida a bolsaNov 03, 2023
Director ejecutivoTownsend (R. Nolan)
Número de empleados72
Tipo de seguridadOrdinary Share
Fin del año fiscalNov 03
Dirección345 Park Avenue South
CiudadNEW YORK
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísUnited States of America
Código postal10010
Teléfono12125479879
Sitio Webhttps://www.lexeotx.com/
Símbolo de cotizaciónLXEO
Fecha de salida a bolsaNov 03, 2023
Director ejecutivoTownsend (R. Nolan)
Ejecutivos de Lexeo Therapeutics Inc
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Louis Tamayo
Mr. Louis Tamayo
Chief Financial Officer, Principal Accounting Officer
Chief Financial Officer, Principal Accounting Officer
89.67K
+44665.00%
Dr. Jose Manuel Otero, Ph.D.
Dr. Jose Manuel Otero, Ph.D.
Chief Technical Officer
Chief Technical Officer
70.98K
+65000.00%
Dr. Eric Adler, M.D.
Dr. Eric Adler, M.D.
Chief Medical Officer and Head of Research
Chief Medical Officer and Head of Research
10.42K
-615.00%
Mr. R. Nolan Townsend
Mr. R. Nolan Townsend
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Dr. Steven M. (Steve) Altschuler, M.D.
Dr. Steven M. (Steve) Altschuler, M.D.
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Ms. Jenny R. Robertson, J.D.
Ms. Jenny R. Robertson, J.D.
Chief Legal Officer
Chief Legal Officer
--
--
Ms. Mette Kirstine Agger
Ms. Mette Kirstine Agger
Independent Director
Independent Director
--
--
Ms. Paula H. J. Cholmondeley
Ms. Paula H. J. Cholmondeley
Independent Director
Independent Director
--
--
Dr. Brenda Cooperstone, M.D.
Dr. Brenda Cooperstone, M.D.
Independent Director
Independent Director
--
--
Mr. Reinaldo M. Diaz
Mr. Reinaldo M. Diaz
Independent Director
Independent Director
--
--
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Louis Tamayo
Mr. Louis Tamayo
Chief Financial Officer, Principal Accounting Officer
Chief Financial Officer, Principal Accounting Officer
89.67K
+44665.00%
Dr. Jose Manuel Otero, Ph.D.
Dr. Jose Manuel Otero, Ph.D.
Chief Technical Officer
Chief Technical Officer
70.98K
+65000.00%
Dr. Eric Adler, M.D.
Dr. Eric Adler, M.D.
Chief Medical Officer and Head of Research
Chief Medical Officer and Head of Research
10.42K
-615.00%
Mr. R. Nolan Townsend
Mr. R. Nolan Townsend
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Dr. Steven M. (Steve) Altschuler, M.D.
Dr. Steven M. (Steve) Altschuler, M.D.
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Ms. Jenny R. Robertson, J.D.
Ms. Jenny R. Robertson, J.D.
Chief Legal Officer
Chief Legal Officer
--
--
Desglose de ingresos
FY2023
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
La empresa aún no ha revelado los datos relevantes.
Por regiónUSD
Nombre
Ganancia
Proporción
United States
0.00
0.00%
Por negocio
Por región
La empresa aún no ha revelado los datos relevantes.
Estadísticas de accionistas
Actualizado: mar., 3 de feb
Actualizado: mar., 3 de feb
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
Janus Henderson Investors
8.37%
RA Capital Management, LP
6.85%
Frazier Life Sciences Management, L.P.
6.06%
Affinity Asset Advisors LLC
5.96%
Balyasny Asset Management LP
5.36%
Otro
67.40%
Accionistas
Accionistas
Proporción
Janus Henderson Investors
8.37%
RA Capital Management, LP
6.85%
Frazier Life Sciences Management, L.P.
6.06%
Affinity Asset Advisors LLC
5.96%
Balyasny Asset Management LP
5.36%
Otro
67.40%
Tipos de accionistas
Accionistas
Proporción
Hedge Fund
38.83%
Investment Advisor/Hedge Fund
19.22%
Venture Capital
11.97%
Investment Advisor
11.49%
Private Equity
6.56%
Research Firm
3.53%
Individual Investor
0.85%
Family Office
0.05%
Bank and Trust
0.04%
Otro
7.45%
Participación institucional
Actualizado: jue., 1 de ene
Actualizado: jue., 1 de ene
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q4
217
65.38M
89.57%
+9.99M
2025Q3
189
48.60M
66.59%
+5.10M
2025Q2
181
40.60M
122.31%
+231.62K
2025Q1
174
34.46M
103.80%
-3.48M
2024Q4
155
35.40M
107.08%
+416.99K
2024Q3
127
33.64M
101.76%
+2.87M
2024Q2
112
31.41M
96.45%
+1.88M
2024Q1
92
30.30M
97.67%
+5.87M
2023Q4
45
23.22M
87.68%
+3.57M
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
Janus Henderson Investors
6.11M
8.37%
+2.42M
+65.71%
Sep 30, 2025
RA Capital Management, LP
5.00M
6.85%
+5.00M
--
Oct 20, 2025
Frazier Life Sciences Management, L.P.
4.42M
6.06%
--
--
Sep 30, 2025
Affinity Asset Advisors LLC
3.87M
5.3%
+281.17K
+7.83%
Sep 30, 2025
Balyasny Asset Management LP
3.91M
5.36%
-95.35K
-2.38%
Sep 30, 2025
The Vanguard Group, Inc.
2.23M
3.05%
+223.42K
+11.16%
Sep 30, 2025
Citadel Advisors LLC
3.72M
5.1%
+111.08K
+3.08%
Sep 30, 2025
Paradigm BioCapital Advisors LP
3.67M
5.03%
+3.67M
--
Nov 13, 2025
Vestal Point Capital, LP
3.25M
4.45%
+21.84K
+0.68%
Sep 30, 2025
Longitude Capital Management Co., LLC
2.77M
3.79%
--
--
Sep 30, 2025
Ver más
ETFs relacionados
Actualizado: sáb., 6 de dic
Actualizado: sáb., 6 de dic
Nombre
Proporción
ProShares Ultra Nasdaq Biotechnology
0.06%
Invesco Nasdaq Biotechnology ETF
0.05%
iShares Micro-Cap ETF
0.05%
iShares Biotechnology ETF
0.04%
iShares Russell 2000 Value ETF
0.02%
Avantis US Small Cap Equity ETF
0.02%
ProShares UltraPro Russell2000
0.01%
Proshares Ultra Russell 2000
0.01%
iShares Russell 2000 ETF
0.01%
Global X Russell 2000 ETF
0.01%
Ver más
ProShares Ultra Nasdaq Biotechnology
Proporción0.06%
Invesco Nasdaq Biotechnology ETF
Proporción0.05%
iShares Micro-Cap ETF
Proporción0.05%
iShares Biotechnology ETF
Proporción0.04%
iShares Russell 2000 Value ETF
Proporción0.02%
Avantis US Small Cap Equity ETF
Proporción0.02%
ProShares UltraPro Russell2000
Proporción0.01%
Proshares Ultra Russell 2000
Proporción0.01%
iShares Russell 2000 ETF
Proporción0.01%
Global X Russell 2000 ETF
Proporción0.01%
Dividendos
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos
División de acciones
Fecha
Fecha ex-dividendo
Tipo
Relación
Sin datos
Fecha
Fecha ex-dividendo
Tipo
Relación
Sin datos
